RRM2 antibody [N1C1]
GTX103193
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat, Zebra Fish
TargetRRM2
Overview
- SupplierGeneTex
- Product NameRRM2 antibody [N1C1]
- Delivery Days Customer9
- Application Supplier NoteICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.28 mg/ml
- ConjugateUnconjugated
- Gene ID6241
- Target nameRRM2
- Target descriptionribonucleotide reductase regulatory subunit M2
- Target synonymsC2orf48, R2, RR2, RR2M, ribonucleoside-diphosphate reductase subunit M2, ribonucleotide reductase M2 polypeptide, ribonucleotide reductase small chain, ribonucleotide reductase small subunit, uncharacterized protein C2orf48
- HostRabbit
- IsotypeIgG
- Protein IDP31350
- Protein NameRibonucleoside-diphosphate reductase subunit M2
- Scientific DescriptionThis gene encodes one of two non-identical subunits for ribonucleotide reductase. This reductase catalyzes the formation of deoxyribonucleotides from ribonucleotides. Synthesis of the encoded protein (M2) is regulated in a cell-cycle dependent fashion. [provided by RefSeq]
- ReactivityHuman, Mouse, Rat, Zebra Fish
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Giang LH, Wu KS, Lee WC, et al. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. J Exp Clin Cancer Res. 2023,42(1):346. doi: 10.1186/s13046-023-02911-xRead this paper
- Baroni M, Guardia GDA, Lei X, et al. The RNA-Binding Protein Musashi1 Regulates a Network of Cell Cycle Genes in Group 4 Medulloblastoma. Cells. 2021,11(1). doi: 10.3390/cells11010056Read this paper
- Muñoz-Montaño W, Muñiz-Hernández S, Avilés-Salas A, et al. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer. 2021,21(1):892. doi: 10.1186/s12885-021-08287-5Read this paper
- Kollareddy M, Martinez LA. Distinct Classes of Flavonoids and Epigallocatechin Gallate, Polyphenol Affects an Oncogenic Mutant p53 Protein, Cell Growth and Invasion in a TNBC Breast Cancer Cell Line. Cells. 2021,10(4). doi: 10.3390/cells10040797Read this paper
- Baroni M, Yi C, Choudhary S, et al. Musashi1 Contribution to Glioblastoma Development via Regulation of a Network of DNA Replication, Cell Cycle and Division Genes. Cancers (Basel). 2021,13(7). doi: 10.3390/cancers13071494Read this paper
- Thege FI, Gruber CN, Cardle II, et al. anti-EGFR capture mitigates EMT- and chemoresistance-associated heterogeneity in a resistance-profiling CTC platform. Anal Biochem. 2019,577:26-33. doi: 10.1016/j.ab.2019.02.003Read this paper
- Su YF, Wu TF, Ko JL, et al. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One. 2014,9(3):e91644. doi: 10.1371/journal.pone.0091644Read this paper




